Novartis AG
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NOTA.F | AMGN | 0QOK.IL | AZN | 0QYQ.IL | BIIB | |
|---|---|---|---|---|---|---|
| Market cap | 271.96B | 258.68B | 334.08B | 293.14B | 217.96B | 37.61B |
| P/E (TTM) | 32.1 | 27.7 | 30.3 | 26.7 | 40.2 | 110.2 |
| Forward P/E | 21.3 | 19.5 | — | 16.7 | — | 15.6 |
| Price/book | 8.2 | 18.0 | 11.9 | 5.7 | 10.3 | 2.0 |
| Dividend yield | 2.90% | 2.11% | 3.99% | 1.69% | 3.81% | — |
| 1-year change | +30.00% | +51.61% | +21.81% | +12.81% | +40.64% | +62.35% |
| Today | 0.00% | +3.73% | +21.55% | +2.79% | +1.70% | +2.22% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All NOTA.F news ›Korea approves Novartis' Vanrafia, first selective ETA blocker for IgA nephropathy
Novartis Korea said Wednesday that Korea has approved Vanrafia (atrasentan) for adults with IgA nephropathy, making it the country's first selective endothelin A (ETA) receptor antagonist approved to treat the kidney disease. The Ministry…
How Novartis optimized its supply chain with real-time risk insight
How Xoople transforms Earth data into business insights How AI drove Daikin’s business transformation from complexity to agility How humanoid robotics are strengthening complex industrial work Can disciplined ambition unlock growth in a…
Novartis Exits BrainTransporter Deal with BioArctic 14 Months After Signing
Novartis exits its BrainTransporter deal with BioArctic 14 months after signing, citing an internal portfolio decision unrelated to the platform. Novartis has terminated its collaboration with BioArctic AB, ending a partnership designed to…
Novartis ends BioArctic brain-delivery deal worth up to $802M
Swedish biotech BioArctic has lost a partnership with Swiss drugmaker Novartis to develop a potential treatment for neurodegenerative diseases using its BrainTransporter technology. The termination eliminates the prospect of up to $772…
More from 1 other outlet
Novartis Exits $800M BioArctic Brain-Delivery Pact After 14 Months
Novartis Pharma AG has pulled out of a neuroscience partnership with Sweden's BioArctic AB (BIOA B.ST) barely 14 months after signing it, leaving the Swedish biotech without the roughly $772 million in milestone payments that hinged on the…
Novartis Heart Drug Fails Major Trial, Raising Questions Over Genetic Cholesterol Treatment
NEW YORK, Nov 2: A major clinical trial failure involving an experimental heart medicine developed by Novartis and Ionis Pharmaceuticals has raised fresh questions about whether lowering a genetically determined form of cholesterol can…
South Korea Approves Novartis Banrapia for Kidney Disease IgAN: First Country Outside US
Vanrafia (atrasentan) wins MFDS approval in South Korea for IgA nephropathy, making Korea the first country outside the US to clear a selective ET-A receptor antagonist for kidney disease.
Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target
pharma.economictimes.indiatimes.com
Hypercholesterolemia Market Projected to Achieve Substantial Growth by 2036, Led by Key Companies and Strategic Developments | Novartis, Esperion Therapeutics, Esperion Therapeutics, EPIC BIO, Amytrx
Hypercholesterolemia Market Projected to Achieve Substantial openPR.com Hypercholesterolemia Market Projected to Achieve Substantial Growth by 2036, Led by Key Companies and Strategic Developments | Novartis, Esperion Therapeutics,…
Stock Market Today: Dow Jones, S&P 500, Nasdaq 10 Futures Gain as Fed Begins Its Two-Day Meet— Novartis, HSBC, Welltower in Focus (UPDATED)
Editor’s Note: The ETFs tracking benchmark indices, lede, economic data, and the headline were updated in the story. U.S. stock futures pared losses to advance Tuesday, as the Dow Jones, S&P 500, and Nasdaq 100 indices rose, following…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com36
- seekingalpha.com7
- novartis.com6
- tradingview.com5
- openpr.com4
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 98 articles, not a forecast.